Chemotherapy-Induced Peripheral Neuropathy: The Side Effect That Outlasts the Treatment
The treatment finished. Everyone told you the hard part was over. And then your feet stayed numb. Buttons became difficult. You started watching the floor when you walked because your feet stopped reporting back reliably. Perhaps you mentioned it and were told it might improve with time, which was honest but not especially useful on a Tuesday afternoon when you could not feel the stairs. Chemotherapy-induced peripheral neuropathy is one of the most common lasting effects of cancer treatment, and one of the least well served. It deserves a clearer explanation than most people get, and there is more that can be done about it than most people are told. How Common It Actually Is Depending on the drug and the cumulative dose, somewhere between a third and two thirds of people receiving neurotoxic chemotherapy develop peripheral neuropathy. Platinum agents and taxanes are among the most frequently implicated. For some, it fades over the months after treatment ends. For a substantial number it does not, and becomes a long-term feature of life afterwards. It is significant enough that it is one of the common reasons chemotherapy doses get reduced or stopped early, which makes it a problem worth taking seriously well before it becomes permanent. If you are experiencing it, you are not an unusual case and you are not complaining about something minor. What Is Actually Happening to the Nerves Chemotherapy is designed to act on rapidly dividing cells. Peripheral nerves are caught in the crossfire, and the longest nerves in the body — those reaching the feet and hands — are the most exposed, which is why symptoms start at the extremities and work inward. The damage involves the nerve fibre itself, disruption to mitochondrial function within the nerve, oxidative stress and inflammatory changes. What that produces is a nerve that is still physically present but not conducting properly. That distinction matters, because it is the reason scans and standard tests so often look unremarkable while your hands plainly do not work the way they used to. The structure is there. The signal is not. At Nerve Health Institute we call that layer EnergyFlow, and it is what we assess. Why Medication Alone Often Disappoints Current oncology guidance is candid about this in a way that surprises most patients. No medication has been established as effective at preventing this neuropathy. For treating it once established, guideline panels have identified only one drug with reasonable supporting evidence — duloxetine — and even that produces partial relief for some rather than resolution for most. Gabapentinoids are widely prescribed and have performed modestly in trials, often limited by side effects. So if you have been prescribed something and found it underwhelming, that is consistent with the evidence rather than a failure on your part or your doctor’s. It also explains why the non-drug approaches have received so much research attention recently. What the Evidence Supports Exercise. This is the strongest of the non-pharmacological options and is increasingly recognised in oncology guidance as a supportive care measure during and after treatment. Systematic reviews report improvements in neuropathy symptoms, pain threshold, balance and strength. Programmes generally combine aerobic work, resistance training for major muscle groups, and sensorimotor or balance training, built gradually and around treatment cycles rather than against them. Balance and fall prevention. When your feet cannot report position reliably, the systems that keep you upright lose their main source of information. Targeted balance work addresses this directly, and it matters practically — falls are a genuine risk in this group, not a theoretical one. Sleep and fatigue management. Both interact with neuropathy symptoms and with recovery capacity generally. Other options. Guideline panels have noted acupuncture and scrambler therapy as reasonable to consider, while being clear that larger studies are still needed. Cryotherapy and compression during infusion are being actively studied for prevention. None of these is dramatic, and collectively they outperform what is available in a prescription pad. That is an unusual situation in medicine and worth knowing about. The Wider Picture After Treatment Neuropathy is rarely the only thing people are carrying when they arrive. Fatigue that does not lift, deconditioning from months of reduced activity, disrupted sleep, and a nervous system that has spent a long period in a protective state all tend to arrive together. Those interact: poor sleep worsens pain perception, deconditioning worsens fatigue, and a system held in protection recovers more slowly than one that is not. Working on one piece in isolation tends to underperform. Working on the pattern tends to do better, and that is where an approach that looks at the whole system rather than the presenting symptom earns its place. What an Evaluation Involves A full history. Your treatment regimen, when symptoms began and how they have changed, what else you were carrying before treatment started, and what your current medical team is managing. A detailed neurological examination. Function assessed across the 88 major nerves branching from the brain and spinal cord — mapping where signal is running below capacity rather than assuming the affected areas are only the ones you can feel. Balance and functional capacity. What you can currently do safely, which sets the starting point for everything else. Daily foundations. Sleep, hydration, breathing, light exposure and activity — the inputs that determine how much recovery capacity you have to work with. The output is a plan paced to where you actually are, designed to be shared with your oncology team rather than run in parallel to it. Where Clinic Technologies Fit Plans draw from the non-invasive technologies available at our Lafayette clinic, including Quantum Neurology for targeted nerve function work, PEMF & Grounding, Theralight360, HBOT and BRT Bioresonance. One thing needs saying clearly about timing. If you are in active cancer treatment, or have a current diagnosis, every one of these needs to be cleared with your oncologist before you start. Some modalities are not appropriate during active treatment, and light-based therapy in particular should not be applied